About: Ultra-sensitive nanozyme-based chemiluminescence paper test for rapid diagnosis of SARS-CoV-2 infection

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Ultra-sensitive nanozyme-based chemiluminescence paper test for rapid diagnosis of SARS-CoV-2 infection Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Ultra-sensitive nanozyme-based chemiluminescence paper test for rapid diagnosis of SARS-CoV-2 infection
Creator	Yan, Jinghua Yan, Xiyun Liu, Dan Chen, Xuehui Han, Chenhui, Ju Duan, Demin Shi, Rui
Source	BioRxiv
abstract	The recently emerged coronavirus disease COVID-19 has now evolved into a global pandemic. Early detection is crucial for its effective control. Nucleic acid testing for viral pathogen and serological testing for host antibodies are playing important roles in current COVID-19 diagnosis. However, while nucleic acid testing is complicated, facility-restricted and time-consuming, antibody testing may result in high rates of false-negative diagnoses, especially during the early stages of viral infection. Thus, a more rapid and reliable test for both early COVID-19 diagnosis and whole-population screening is urgently needed. Here, we developed a novel nanozyme-based chemiluminescence paper assay for rapid and high-sensitive testing of SARS-CoV-2 spike antigen. Our paper test uses a newly established peroxidase-mimic Co-Fe@hemin nanozyme instead of natural HRP that catalytically amplifies the chemiluminescent signal, allowing for target concentrations to be as low as 0.1 ng/ml. Furthermore, our nanozyme-based chemiluminescence test exhibits a linear range that is 32-fold wider compared to ELISA tests. Importantly, testing is completed in less than 16 min, compared to 1-2 h required for ELISA or nucleic acid tests. Critically, signal detection is feasible using a smartphone camera. Ingredients for our test are simple and readily available, rendering overall cost considerably lower than those used in current diagnoses. In conclusion, our novel test provides a high-sensitive, point-of-care testing (POCT) approach for SARS-CoV-2 antigen detection, which should greatly increase current early screening capacities for suspected infections, and considerably lower demand for national healthcare resources.
has issue date	2020-06-05(xsd:dateTime)
bibo:doi	10.1101/2020.06.05.131748
has license	biorxiv
sha1sum (hex)	9c68a17c2f1c52b9c531eac7f1bc93cd70ccb745
schema:url	https://doi.org/10.1101/2020.06.05.131748
resource representing a document's title	Ultra-sensitive nanozyme-based chemiluminescence paper test for rapid diagnosis of SARS-CoV-2 infection
schema:publication	bioRxiv
resource representing a document's body	covid:9c68a17c2f1c52b9c531eac7f1bc93cd70ccb745#body_text
is schema:about of	named entity 'hemin' named entity 'concentrations' named entity 'min' named entity 'test' named entity 'paper' named entity 'IMPORTANT' named entity 'TIME-CONSUMING' named entity 'ALLOWING' named entity 'RECENTLY' named entity '1-2' named entity 'EARLY' named entity 'BASED' named entity 'acid' named entity 'national healthcare' named entity 'Here' named entity 'result' named entity 'rendering' named entity 'Our' named entity 'test' named entity 'COVID-19' named entity 'detection' named entity 'testing' named entity 'antibody testing' named entity 'compared' named entity 'cost' named entity 'natural' named entity 'test' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'nanozyme' named entity 'nucleic acid tests' named entity 'POCT' named entity 'infection' named entity 'room temperature' named entity 'TP52' named entity 'immunoassay' named entity 'reverse transcription' named entity 'elemental analysis' named entity 'chemiluminescence' named entity 'SARS-CoV-2' named entity 'nanozyme' named entity 'nanozyme' named entity 'DLS' named entity 'nucleic acid testing' named entity 'CLIA' named entity 'SARS-CoV-2' named entity 'peroxidase' named entity 'nanozyme' named entity 'calibration curve' named entity 'protein' named entity 'carboxyl group' named entity 'cDNA' named entity 'HCoV-HKU1' named entity 'Antibody testing' named entity 'socio-economic' named entity 'nucleic acid detection' named entity 'vaccine' named entity 'UV-Vis' named entity 'nanozyme' named entity 'scanning electron microscopy' named entity 'nucleic acid testing' named entity 'room temperature' named entity 'antibody tests' named entity 'lateral flow' named entity 'CB6' named entity 'transfecting' named entity 'antibodies' named entity 'RNA extraction' named entity 'chemiluminescence' named entity 'nanozyme' named entity 'CLIA' named entity 'epidemiological' named entity 'antibody' named entity 'microscope' named entity 'virus' named entity 'antibody test' named entity 'oxidated'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software